Evaluation of tumor M2-pyruvate kinase (Tumor M2-PK) as a biomarker for pancreatic cancer.

about

The Use of Biomarkers in Early Diagnostics of Pancreatic Cancer

P2860

Q58780532-B6390798-1B05-4194-A7E0-E1FD4F5E47FA

P2860

Evaluation of tumor M2-pyruvate kinase (Tumor M2-PK) as a biomarker for pancreatic cancer.

Item

http://www.wikidata.org/entity/Q54982152

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Evaluation of tumor M2-pyruvat ...... omarker for pancreatic cancer.

@en

Evaluation of tumor M2-pyruvate kinase

@nl

type

Item

label

Evaluation of tumor M2-pyruvat ...... omarker for pancreatic cancer.

@en

Evaluation of tumor M2-pyruvate kinase

@nl

prefLabel

Evaluation of tumor M2-pyruvat ...... omarker for pancreatic cancer.

@en

Evaluation of tumor M2-pyruvate kinase

@nl

P1476

Evaluation of tumor M2-pyruvat ...... omarker for pancreatic cancer.

@en

P2093

Indika A Bandara

http://www.w3.org/2001/XMLSchema#string

Minas Baltatzis

http://www.w3.org/2001/XMLSchema#string

Sudip Sanyal

http://www.w3.org/2001/XMLSchema#string

P2860

Human pyruvate kinase M2: a multifunctional protein

The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth

Tumor M2-PK and glutaminolytic enzymes in the metabolic shift of tumor cells.

The combination of the expression of hexokinase 2 and pyruvate kinase M2 is a prognostic marker in patients with pancreatic cancer.

Pyruvate Kinase M2 and Lactate Dehydrogenase A Are Overexpressed in Pancreatic Cancer and Correlate with Poor Outcome

PKM2 promotes tumor angiogenesis by regulating HIF-1α through NF-κB activation

Pyruvate kinase M2 overexpression and poor prognosis in solid tumors of digestive system: evidence from 16 cohort studies.

Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells.

Comparison of plasma Tu-M2-PK and CA19-9 in pancreatic cancer.

The concentration of D-dimers in portal blood positively correlates with overall survival in patients with non-resectable pancreatic cancer.

P2888

s12957-018-1360-3

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12957-018-1360-3

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Ajith K Siriwardena

P577

2018-03-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1101529802

http://www.w3.org/2001/XMLSchema#string

P698

29540198

http://www.w3.org/2001/XMLSchema#string

P921

biomarker

P932

5853155

http://www.w3.org/2001/XMLSchema#string

Evaluation of tumor M2-pyruvate kinase (Tumor M2-PK) as a biomarker for pancreatic cancer.

about

P2860

P2860

Evaluation of tumor M2-pyruvate kinase (Tumor M2-PK) as a biomarker for pancreatic cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P921

P932